Satoru Kakizaki

18PUBLICATIONS
52CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Gene expression (incl. microarray and other genome-wide approaches)Nutrigenomics and personalised nutritionPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|May 03, 2025
Antitumor effects and immune-mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma.

Takanori Ito, Shigeo Shimose, Joji Tani

|May 03, 2025
Impact of time-of-day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter study.

Atsushi Naganuma, Satoru Kakizaki, Takeshi Hatanaka

|Nov 11, 2024
Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice.

Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka

|Jul 11, 2024
Evaluation of the associations of interlukin-7 genetic variants with toxicity and efficacy of immune checkpoint inhibitors: A replication study of a Japanese population, based on the findings of a European genome-wide association study.

Hideaki Miyamoto, Yasuteru Kondo, Ei Itobayashi

|Jun 12, 2023
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada

|Nov 17, 2022
Correction to: Development and validation of a modified albumin-bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab.

Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka

Pageof 3

Frequent Collaborators

14 joint publications

Takeshi Hatanaka

11 joint publications

Atsushi Naganuma

10 joint publications

Hidenori Toyoda

10 joint publications

Atsushi Hiraoka